A Phase 1 interventional study of Prednisolone and Bronchoscopy in Asthma, sponsored by GlaxoSmithKline. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-08-04.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing prednisolone in Asthma — none open to participants now, 1 under way, none of them phase 3. Prednisolone · Asthma.
Among the 15 studies testing prednisolone in Asthma, this one is the 13th largest by enrollment, is one of 2 that started in 2005, is the only one in phase 1, and was the 3rd registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →None of the 15 studies testing prednisolone in Asthma is open now. The open studies under Asthma, anywhere →
Prednisolone: first FDA approval 1955 (METICORTELONE). What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 158 across the 15 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 15 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 152nd largest by enrollment of the 238 interventional ones that give a count, is one of 17 that started in 2005, is one of 62 in phase 1, and was the 17th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing prednisolone in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
To evaluate and compare the expression and change in expression of key severe asthma targets at baseline in mile to moderate asthmatics vs. severe asthmatic subjects.
To evaluate and compare the airway pathology at baseline and changes in airway pathology in relation to asthma severity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
In addition, the following additional exclusion criteria must apply to mild to moderate persistent asthmatics on regular inhaled :
In addition, the following additional exclusion criteria must apply to severe persistent asthmatics with clinical controlled asthma symptoms:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Asymptomatic subjects receiving only beta-agonist inhaler with predicted FEV1 \>=80% and normal peak expiratory flow between attacks will be included.
Drug: Prednisolone · Procedure: Bronchoscopy
Subjects with mild to moderate persistent asthma on low to moderate dose of inhaled corticosteroid (200-500 microgram fluticasone propionate daily or equivalent), an FEV1 \>= 80% predicted (post-bronchodilator), and less than 20% variability in peak expiratory flow.
Drug: Prednisolone · Procedure: Bronchoscopy
Subjects with severe persistent asthma. They will be on either: high inhaled corticosteroid (CS \>=1000 microgram fluticasone daily or equivalent) or on high dose inhaled CS plus oral CS (no more than 20 milligrams predisolone a day). The subjects should have at least one ( if on oral steroids) or two (if only on inhaled steroids) of the following: 1) FEV1\<80% and FEV1/FVC ratio \<70% 2) more than 25% variability in peak expiratory flow 3) daily symptoms ± nocturnal symptoms 4) severe exacerbations of \>= twice a year in at least one of the last two years.
Drug: Prednisolone · Procedure: Bronchoscopy
Non-asthmatic and non-smokers with FEV1 \> 85% predicted, on no regular medication.
Procedure: Bronchoscopy
Subjects will be administered oral prednisolone at a dose of 0.5 mg/kg, up to a maximum of 40 mg per day for 14 days.
All subjects will undergo bronchoscopy assessments which will involve insertion of a standard bronchoscope.
Airway pathology endpoints Target Validation endpoints Biomarker endpoints Clinical endpoints
biomarkers, vital signs, ECG
Time frame: Through 2 weeks of Prednisolone dosing
Expression of airway and systemic biomarkers. Relationship between changes in target expression and clinical measures of disease activity. Relationship between steady state plasma exposure of prednisolone and pharmacodynamic biomarkers.
biomarkers
Time frame: Through 2 weeks of prednisolone dosing.
Ran from Aug 2005 to primary completion in Jun 2011, 70 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prednisolone